Mizuho lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $5.50 from $12 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital
- Adverum Biotechnologies’ Phase 3 Study on Ixo-vec: A Potential Game-Changer for AMD Treatment
- Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
- M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push
- Adverum Biotechnologies downgraded to Hold from Buy at Truist